Filtered By:
Infectious Disease: Hepatitis B

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 12703 results found since Jan 2013.

5'-triphosphate-siRNA activates RIG-I-dependent type I interferon production and enhances inhibition of hepatitis B virus replication in HepG2.2.15 cells.
In conclusion, our findings suggest that 3p-siRNA could act as a powerful bifunctional antiviral molecule with potential for developing a promising therapeutic against chronic HBV infection. PMID: 24099962 [PubMed - as supplied by publisher]
Source: European Journal of Pharmacology - October 4, 2013 Category: Drugs & Pharmacology Authors: Chen X, Qian Y, Yan F, Tu J, Yang X, Xing Y, Chen Z Tags: Eur J Pharmacol Source Type: research

Targeted Delivery of siRNA against Hepatitis B Virus by PreS1 Peptide Molecular Ligand
ConclusionThe results indicated that PreS1‐9Arg may be a potential novel vector to deliver siRNA targeting liver cells.
Source: Hepatology Research - June 28, 2013 Category: Internal Medicine Authors: Wenjuan Huang, Xia Li, Min Yi, Sufen Zhu, Weixian Chen Tags: Original Article Source Type: research

Hepatic Stellate Cells in Liver Fibrosis and siRNA-Based Therapy.
Abstract Hepatic fibrosis is a reversible wound-healing response to either acute or chronic liver injury caused by hepatitis B or C, alcohol, and toxic agents. Hepatic fibrosis is characterized by excessive accumulation and reduced degradation of extracellular matrix (ECM). Excessive accumulation of ECM alters the hepatic architecture leading to liver fibrosis and cirrhosis. Cirrhosis results in failure of common functions of the liver. Hepatic stellate cells (HSC) play a major role in the development of liver fibrosis as HSC are the main source of the excessive production of ECM in an injured liver. RNA interfere...
Source: Pharmacological Reviews - August 17, 2016 Category: Drugs & Pharmacology Authors: Omar R, Yang J, Liu H, Davies NM, Gong Y Tags: Rev Physiol Biochem Pharmacol Source Type: research

Targeting cancer cell-specific RNA interference by siRNA delivery using a complex carrier of affibody-displaying bio-nanocapsules and liposomes
Conclusions: These findings show that, in the field of nucleic acid medicine, ZHER2-BNC/LP can be a useful carrier for siRNA delivery, and could also become a useful tool for gene silencing and to accomplish protein knock-down.
Source: Journal of Nanobiotechnology - June 24, 2013 Category: Nanotechnology Authors: Yuya NishimuraHiroaki MiedaJun IshiiChiaki OginoToshinobu FujiwaraAkihiko Kondo Source Type: research

TLR4 Influences Hepatitis B Virus Related Hepatocellular Carcinoma by Regulating the Wnt/ β-Catenin Pathway
Conclusions: TLR4 can affect the expression of β-catenin and hence influence the progression of HBV-related HCC.Cell Physiol Biochem 2017;42:469 –479
Source: Cellular Physiology and Biochemistry - June 2, 2017 Category: Cytology Source Type: research

siRNA nanotherapeutics: a promising strategy for anti-HBV therapy
Chronic hepatitis B (CHB) is the most common cause of hepatocellular carcinoma (HCC) and liver cirrhosis worldwide. In spite of the numerous advances in the treatment of CHB, drugs and vaccines have failed because of many factors like complexity, resistance, toxicity, and heavy cost. New RNA interference (RNAi)-based technologies have developed innovative strategies to target Achilles' heel of the several hazardous diseases involving cancer, some genetic disease, autoimmune illnesses, and viral disorders particularly hepatitis B virus (HBV) infections. Naked siRNA delivery has serious challenges including failure to cross ...
Source: IET Nanobiotechnology - June 21, 2019 Category: Nanotechnology Source Type: research

PreS/2-21-Guided siRNA Nanoparticles Target to Inhibit Hepatitis B Virus Infection and Replication
A viable therapy is needed to overcome the deadlock of the incurable chronic hepatitis B (CHB). The prolonged existence of covalently closed circular DNA (cccDNA) and integrated HBV DNA in the nucleus of hepatocytes is the root cause of CHB. As a result, it is critical to successfully suppress HBV DNA replication and eliminate cccDNA. RNA interference has been proven in recent research to silence the expression of target genes and thereby decrease HBV replication. However, siRNA is susceptible to be degraded by RNA enzymes in vivo, making it difficult to deliver successfully and lacking of tissue targeting. To exploit the ...
Source: Frontiers in Immunology - April 29, 2022 Category: Allergy & Immunology Source Type: research

SiRNA-targeted carboxypeptidase D inhibits hepatocellular carcinoma growth.
Abstract Carboxypeptidase D (CPD), a membrane-bound metallocarboxypeptidase that functions as a docking receptor for duck hepatitis B virus, is frequently overexpressed in human cancers. We have explored its expression pattern, clinical significance, and biological function of CPD in hepatocellular carcinoma (HCC). CPD expression was markedly elevated in HCCs relative to adjacent non-tumor liver tissues, as determined by quantitative real-time polymerase chain reaction and Western blot analysis. Immunohistochemistry showed that 164 of 400 (41%) HCCs had high expression of CPD. CPD overexpression was significantly ...
Source: Cell Biology International - April 16, 2013 Category: Cytology Authors: Jin T, Fu J, Feng XJ, Wang SM, Huang X, Zhu MH, Zhang SH Tags: Cell Biol Int Source Type: research

5'-triphosphate siRNA targeting HBx elicits a potent anti-HBV immune response in pAAV-HBV transfected mice.
Abstract RNA with 5'-triphosphate (3p-RNA) is recognized by RNA sensor RIG-I (retinoic acid-inducible gene I protein). Previously, we reported that small interfering RNA targeting HBx (3p-siHBx) could confer potent anti-hepatitis B virus (HBV) efficacy via HBx silencing and RIG-I activation. However, the characteristics of innate and adaptive immunity especially exhaustion profiles in the liver microenvironment in response to 3p-siHBx therapy have not been fully elucidated. Here, we observed that 3p-siHBx more significantly inhibited HBV replication in vivo. 3p-siHBx enhanced natural killer (NK) cell activation wi...
Source: Antiviral Research - November 15, 2018 Category: Virology Authors: Han Q, Hou Z, Yin C, Zhang C, Zhang J Tags: Antiviral Res Source Type: research

Routine childhood vaccination programme coverage, El Salvador, 2011-In search of timeliness.
Abstract While assessing immunization programmes, not only vaccination coverage is important, but also timely receipt of vaccines. We estimated both vaccination coverage and timeliness, as well as reasons for non-vaccination, and identified predictors of delayed or missed vaccination, for vaccines of the first two years of age, in El Salvador. We conducted a cluster survey among children aged 23-59 months. Caregivers were interviewed about the child immunization status and their attitudes towards immunization. Vaccination dates were obtained from children immunization cards at home or at health facilities. We refe...
Source: Vaccine - December 3, 2013 Category: Allergy & Immunology Authors: Suárez-Castaneda E, Pezzoli L, Elas M, Baltrons R, Crespin-Elías EO, Pleitez OA, de Campos MI, Danovaro-Holliday MC Tags: Vaccine Source Type: research

The search is on for a hepatitis B drug, thanks to a million dollars in NIH grants to SLU
(Saint Louis University) Two grants from the National Institutes of Health will allow Saint Louis University researchers to build on breakthroughs in understanding the hepatitis B virus and begin the search for a drug to cure -- not just halt -- the illness.
Source: EurekAlert! - Medicine and Health - March 25, 2014 Category: Global & Universal Source Type: news

Search for a cure for chronic hepatitis B infection: How close are we?
Authors: Phyo WW, Soh AY, Lim SG, Lee GH Abstract Chronic hepatitis B (CHB) remains a significant unmet medical need, with 240 million chronically infected persons worldwide. It can be controlled effectively with either nucleoside/nucleotide-based or interferon-based therapies. However, most patients receiving these therapies will relapse after treatment withdrawal. During recent years, the advances in molecular biology and immunology have enabled a better understanding of the viral-host interaction and inspired new treatment approaches to achieve either elimination of the virus from the liver or durable immune con...
Source: World Journal of Hepatology - May 30, 2015 Category: Gastroenterology Tags: World J Hepatol Source Type: research

Current status of immunomodulatory therapy in chronic hepatitis B, fifty years after discovery of the virus: search for the "magic bullet" to kill cccDNA.
This article forms part of a symposium in Antiviral Research on "An unfinished story: from the discovery of the Australia antigen to the development of new curative therapies for hepatitis". PMID: 26476376 [PubMed - as supplied by publisher]
Source: Antiviral Research - October 14, 2015 Category: Virology Authors: Zhang E, Kosinska A, Lu M, Yan H, Roggendorf M Tags: Antiviral Res Source Type: research

Search of Hepatitis-B infection in relatives of chronic carriers in the province of Huanta, Ayacucho, Peru.
In conclusion, we found a high frequency of HBV in relatives of carriers of HBsAg. This strategy would help identify chronic carriers that can be treated and to contribute to a plan for the elimination of HBV. PMID: 30726419 [PubMed - in process]
Source: Revista Peruana de Medicina de Experimental y Salud Publica - February 7, 2019 Category: International Medicine & Public Health Tags: Rev Peru Med Exp Salud Publica Source Type: research

Fifty years in search of selective antiviral drugs.
Abstract Fifty years of research (1968-2018) towards the identification of selective antiviral drugs have been primarily focused on antiviral compounds active against DNA viruses [i.e. herpes simplex virus (HSV), varicella-zoster virus (VZV), cytomegalovirus (CMV), hepatitis B virus (HBV)] and retroviruses [i.e. human immunodeficiency virus (HIV)]. For the treatment of HSV infections the aminoacyl esters of acyclovir were designed, one of which (the valine ester valacyclovir) became the successor of acyclovir in the treatment of HSV and VZV infections. BVDU (Brivudin) still stands out as the most effective among t...
Source: Herpes - April 1, 2019 Category: Infectious Diseases Authors: De Clercq E Tags: J Med Chem Source Type: research